{"Clinical Trial ID": "NCT02015676", "Intervention": ["INTERVENTION 1:", "Trastuzumab, doxorubicin, paclitaxel; phase II", "Participants received an initial loading dose of trastuzumab 4 mg/kg, IV, more than 1.5 hours on day 1 (week 1), followed by 2 mg/kg, IV, more than 30 minutes once a week from week 2 to week 52 or until disease progression; doxorubicin, 50 mg/m^2, IV, once every 3 weeks, from week 1 for 6 cycles; and paclitaxel 80 mg/m^2, IV, once a week, from week 19 to disease progression."], "Eligibility": ["Incorporation criteria:", "Women between 18 and 70 years of age;", "Metastatic or locally advanced breast cancer;", "- HER2 overexpression;", ">= 1 measurable lesion.", "- Exclusion criteria:", "Prior treatment for advanced breast cancer;", "Prior treatment with Herceptin;", "Bone metastases or central nervous system as the only disease site;", "The history of other malignancy (except basal cell skin cancer and cervical in situ cancer and contralateral breast cancer) within 5 years of the study."], "Results": ["Performance measures:", "Percentage of participants receiving a complete (RC) or partial (PR) response According to the World Health Organization (WHO) Manual for Reporting Cancer Treatment Outcomes", "In the case of a measurable disease, the CR was defined as the disappearance of all clinically detectable diseases, determined by 2 separate observations of at least 4 weeks; and the PR was defined as a 50 percent decrease in the sum of the products of the 2 largest diameters of all measurable lesions by 2 separate observations of at least 4 weeks, and no new lesions or progression of any lesions occurred.", "Timeline: Basic data, weeks 7, 13, 19, every 8 weeks thereafter until the end of the study (up to 3 years)", "Results 1:", "Title of arm/group: Trastuzumab, Doxorubicin, Paclitaxel; Phase II", "The participants received an initial loading dose of trastuzumab 4 mg/kg, IV, more than 1.5 hours on day 1 (week 1), followed by 2 mg/kg, IV, more than 30 minutes once a week from week 2 to week 52 or until disease progression; doxorubicin, 50 mg/m^2, IV, once every 3 weeks, from week 1 for 6 cycles; and paclitaxel 80 mg/m^2, IV, once a week, from week 19 to disease progression.", "Total number of participants analysed: 54", "Type of measurement: Number", "Unit of measure: % of participants CR: 51.85", "PR: 46.30"], "Adverse Events": ["Undesirable Events 1:", "Total: 26/69 (37.68 per cent)", "Thrombophlebitis * 1/69 (1.45%)", "Anemia NOS * 1/69 (1.45%)", "\u2022 Acute neutrophil febrile dermatosis * 1/69 (1.45%)", "Heart failure NOS * 2/69 (2.90%)", "Decrease in ejection fraction * 1/69 (1.45%)", "Intestinal exclusion NOS * 1/69 (1.45%)", "- Diarrhoea NOS * 2/69 (2.90%)", "* 12/69 (17.39%)", "Inflammation of the mucous membrane NOS * 1/69 (1.45%)"]}